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This special issue of Genetics Research International focuses
on molecular genetics and cytogenetics in cancer. The hunt for
informative disease-related genetic biomarkers may become
so valuable for the diﬀerential diagnosis, prognosis, and dis-
ease monitoring of cancer patients that numerous research-
ers are committed to this challenge. Indeed, a colossal eﬀort
ofcurrentmolecularmedicinetoprogressintheunderstand-
ing of the hallmarks of cancer is focusing on the ﬁeld of
biomarker discovery through genetic and cytogenetic pro-
ﬁling. Ambitious initiatives such as the Cancer Genome
Atlas (http://cancergenome.nih.gov/) or the Cancer Genome
Anatomy Project (http://cgap.nci.nih.gov/cgap.html)f r o m
the US National Institutes of Health (NIH) are devoted to
provide collaborative platforms to better comprehend and
ﬁght the malignant signature of cancer.
The fast development of high-throughput technologies is
bringing to biomedical research more aﬀordable and high-
resolution ways to explore whole genomes, chromosomes,
genes, proteins, RNA, and metabolites. In consequence,
numerous genomic datasets accumulate in international re-
positories,suchasGEOfromtheUSNationalCenterforBio-
technology Information (NCBI), and around 500,000 clonal
chromosomal abnormalities belonging to more than 60,000
human neoplasms are described in the latest catalogue of
chromosome aberrations in cancer. However, translational
application of biomarker discovery still has to face its ulti-
mate challenge: incorporation into routine clinical practice.
We are under the pressure to combine the multidiscipli-
nary eﬀorts of basic, clinical, and computational research
ﬁelds to identify meaningful genetic proﬁles that can be used
as powerful tools for diagnosis, prognosis, and treatment.
Every patient who suﬀers from cancer hopes that our re-
search will deliver alternatives. For scientists, the identiﬁca-
tion of the speciﬁc genetic abnormalities responsible for tu-
mor diversity and heterogeneity is crucial to shed light on
themolecularmechanismsofcancerandtheidentiﬁcationof
druggabletargetsandfunctionalpathways.Forclinicians,the
appropriatemolecularcategorizationofpatientswouldallow
to enroll them in tailored—more adequate and less toxic—
treatments, improving healthcare and optimizing medical
costs.
Ultimately,anyeﬀortto(i)frametheimportantunsolved
problems, (ii) to review what is known about the molecular
pathways involved in the pathogenesis of distinct types of
cancer,(iii)tocatalogrecurrentgeneticalterationsthatcould
serve as biomarkers, (iv) to suggest standardization of rou-
tine protocols of diagnosis and molecular detection, and (v)
to rank available or potential drugs and their targets, is deci-
sive to help molecular medicine in its challenge against can-
cer. This is the scope of this special issue where the biogra-
phies of some of the most aggressive hematological and solid
tumors are discussed. The journal Genetics Research Inter-
national is serving here as a forum for discussion and review
of major genetic risks involved in breast cancer metastasis
to the brain as well as in the evolution of myxoid soft-
tissue sarcomas and parathyroid tumors. The importance of
applying genetic protocols in the risk-based stratiﬁcation of
multiple myeloma is also reviewed here, and new evidences
supportinggeneticaberrationsinararevariantofT-celllym-
phomas known as S´ ezary syndrome are presented. Finally,2 Genetics Research International
myeloid malignancies are revealed as a paradigm to discuss
the role of dicentric chromosomes as instigators of genomic
instability and suggest a model for their implication in the
formation of unbalanced translocations in malignancy.
Breaking the barriers of cancer is a diﬃcult task that is
continuously challenging the research community.
We, the editors of this special issue, are hopeful that the
ideas presented here can inspire the critical thinking of the
specialized readers and contribute to the common eﬀorts to
better understand and ﬁght the multiple faces of cancer.
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